
Cepheid has secured US FDA clearance and Clinical Laboratory Improvement Amendments (CLIA) waiver for its Xpert Xpress MVP, a multiplex vaginal panel for Bacterial Vaginosis, Vulvovaginal Candidiasis, and Trichomoniasis. The near-patient testing provides results within 60 minutes, demonstrating Cepheid's commitment to women's and sexual health. With diagnoses often relying on clinical examinations, this breakthrough allows targeted treatments, reducing antibiotic overuse and improving patient outcomes. Cepheid's CLIA Waiver for MVP expands access to PCR testing at the point of care, aligning with their dedication to enhancing healthcare.
Like
Save
Share